Free Trial
NASDAQ:SXTP

60 Degrees Pharmaceuticals (SXTP) Stock Price, News & Analysis

60 Degrees Pharmaceuticals logo
$2.28 -0.20 (-8.06%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$2.38 +0.11 (+4.61%)
As of 05/2/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About 60 Degrees Pharmaceuticals Stock (NASDAQ:SXTP)

Key Stats

Today's Range
$2.21
$2.65
50-Day Range
$1.46
$3.45
52-Week Range
$1.41
$35.99
Volume
75,658 shs
Average Volume
551,856 shs
Market Capitalization
$3.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

60 Degrees Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
4th Percentile Overall Score

SXTP MarketRank™: 

60 Degrees Pharmaceuticals scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for 60 Degrees Pharmaceuticals are expected to grow in the coming year, from ($5.09) to ($0.61) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of 60 Degrees Pharmaceuticals is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of 60 Degrees Pharmaceuticals is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about 60 Degrees Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    30.91% of the float of 60 Degrees Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    60 Degrees Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in 60 Degrees Pharmaceuticals has recently increased by 1,360.96%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    60 Degrees Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    60 Degrees Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    30.91% of the float of 60 Degrees Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    60 Degrees Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in 60 Degrees Pharmaceuticals has recently increased by 1,360.96%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    3 people have searched for SXTP on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, 60 Degrees Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.27% of the stock of 60 Degrees Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.96% of the stock of 60 Degrees Pharmaceuticals is held by institutions.

  • Read more about 60 Degrees Pharmaceuticals' insider trading history.
Receive SXTP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 60 Degrees Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SXTP Stock News Headlines

REVEALED: Elon’s Secret Master Plan “AGENDA X”
REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secret. Now, leaked computer code confirms Elon is moments away from launching a revolutionary financial technology… And Silicon Valley insider Jeff Brown says it could hand early investors who missed Tesla, "the ultimate second chance" to get rich.
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals announces 1-for-5 reverse stock split
See More Headlines

SXTP Stock Analysis - Frequently Asked Questions

60 Degrees Pharmaceuticals' stock was trading at $6.45 at the beginning of the year. Since then, SXTP stock has decreased by 64.7% and is now trading at $2.28.
View the best growth stocks for 2025 here
.

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($21.15) EPS for the quarter, missing the consensus estimate of ($13.95) by $7.20. The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.11 million.

60 Degrees Pharmaceuticals shares reverse split on Monday, February 24th 2025. The 1-5 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the market closes on Sunday, February 23rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

60 Degrees Pharmaceuticals (SXTP) raised $7 million in an IPO on Wednesday, July 12th 2023. The company issued 1,400,000 shares at a price of $5.30 per share. WallachBeth Capital LLC acted as the underwriter for the IPO.

Shares of SXTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 60 Degrees Pharmaceuticals investors own include Recursion Pharmaceuticals (RXRX), Editas Medicine (EDIT), Pacific Biosciences of California (PACB), Tilray (TLRY), Akanda (AKAN), Better Therapeutics (BTTX) and Honeywell International (HON).

Company Calendar

Last Earnings
8/14/2024
Today
5/04/2025
Next Earnings (Estimated)
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SXTP
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-3,770,000.00
Pretax Margin
-16,230.61%

Debt

Sales & Book Value

Annual Sales
$607,574.00
Price / Cash Flow
N/A
Book Value
($10.45) per share
Price / Book
-0.22

Miscellaneous

Free Float
6,609,000
Market Cap
$3.36 million
Optionable
Not Optionable
Beta
3.41
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:SXTP) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners